Researchers in NYU Langone’s Division of Pulmonary, Critical Care, and Sleep Medicine conduct multidisciplinary translational and clinical research on bronchiectasis and nontuberculous mycobacteria (NTM).

The NYU Langone Bronchiectasis and NTM Multidisciplinary Program enables our scientists to integrate advances in research with clinical care applied to a large cohort of subjects with NTM disease with or without bronchiectasis. This cohort provides the platform needed to institute clinical trials under Doreen J. Addrizzo-Harris, MD principal investigator, and translational research under Leopoldo N. Segal, MD. Along with their colleagues Ashwin Basavaraj, MD, and David L. Kamelhar, MD , they conduct prospective evaluations of patients with NTM infection, collecting extensive clinical data and data from questionnaires that facilitate study of the natural history of NTM disease. Other members of the research team include Stephanie Lau, MD , Rosemary Schluger, RN, Sana Asad, NP, Thomas McCurdy, NP, Amy Springer, NP, and Danielle Harris.

The program benefits from its multidisciplinary collaboration with specialists in gastroenterology, infectious disease, swallowing disorders, otolaryngology, thoracic radiology, thoracic surgery, pulmonary rehabilitation, chest physical therapy, respiratory therapy, microbiology, and nutrition.

As part of this program, Dr. Segal and his colleagues at the Segal Lab perform research on the airway microbiome. Dr. Segal is evaluating how a disrupted lung microbiome may be necessary for the development of clinically evident NTM infection and bronchiectasis. In addition, he is in charge of developing a biorepository of biological samples collected during the initiation and maintenance of antimycobacterial treatment. The goal is to identify microbial signatures associated with successful suppressive treatment or disease progression that may facilitate identification of new targets for treatment in individual patients.

The program also participates in multicenter studies evaluating novel antibiotic approaches in refractory NTM disease and new therapies for bronchiectasis. Dr. Addrizzo-Harris serves as primary investigator for the NYU Langone section of the COPD Foundation’s Bronchiectasis and NTM Research Registry. NYU Langone is one of the largest contributors to the registry.

Recent Publications

Sulaiman I … Segal LN. Evaluation of the airway microbiome in nontuberculous mycobacteria disease. Eur Respir J. 2018. DOI.

Eden E … Winthrop KL. The clinical features of bronchiectasis associated with alpha-1 antitrypsin deficiency, common variable immunodeficiency and primary ciliary dyskinesia--results from the U.S. Bronchiectasis Research Registry. Chronic Obstr Pulm Dis. 2019. DOI.
 
Basavaraj A … Winthrop KL. Airway clearance techniques in bronchiectasis: Analysis from the United States Bronchiectasis and Non-TB Mycobacteria Research Registry. Chest. 2020. DOI.

Despotes KA … Noone PG. Nutrition and markers of disease severity in patients with bronchiectasis. Chronic Obstr Pulm Dis. 2020. DOI.

Oriano M … Aliberti S. Sputum neutrophil elastase associates with microbiota and Pseudomonas aeruginosa in bronchiectasis. Eur Respir J. 2020. DOI.

Choate R … Stone G. Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The U.S. bronchiectasis and NTM Research Registry (BRR) study. Respir Med. 2020. DOI.

Griffith DE … Winthrop KL. Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease: Sustainability and durability of culture conversion and safety of long-term exposure. Chest. 2021. DOI.

Singh S and Segal LN. A lung pathobiont story: Thinking outside the Koch’s postulate box. Cell Host Microbe. 2022. DOI.

McGuire E … Adrizzo-Harris D. Outcomes of robotic surgery for patients with pulmonary nontuberculous mycobacterial disease. Int J Respir Pulm Med. 2022. DOI.